Former D&D creative director Chris Perkins reflects on what drove 5e's success and how campaign-length adventures mattered ...

Topping the list for one of the cheapest destinations for 2026 is Las Vegas. Skyscanner data reveals that the average prices ...

In this guest blog, Karen McNulty Walsh of Brookhaven National Laboratory explains how Michigan Technological University ...

Why would anyone want to live on Mars? As even enthusiasts for a Martian colony would admit, it would be at best like living permanently in a shopping mall. But for Caleb Scharf, an astrobiologist at ...

Add Yahoo as a preferred source to see more of our stories on Google. Group Travel Company Much Better Adventures (MBA) has just released new booking data pointing to six major adventure travel trends ...

The U.S. Senate Banking Committee will not have any markup hearings on market structure legislation defining how federal regulators can oversee the industry until next year, punting on a hoped-for ...

This coal plant in central Pennsylvania, once the largest in the state, was shuttered in 2023 after powering the region for over 50 years. Earlier this year, wrecking crews blasted the plant’s cooling ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Active travel specialist Backroads has announced its “Top Adventure Travel Trends for 2026,” based on early guest bookings and insights from its worldwide team of Trip Leaders and Travel Experts ...

After weeks of what had been tightly buttoned talks between the parties, Senate Democrats have delivered their latest counteroffer on the crypto market structure bill, outlining a set of demands ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...